Clinical trial · Observational
Liquid Biospy for Urinary Cancers
Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer"
NCT06116396CI-TRIAL-00071104CIRCErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by CTCs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Urothelial Carcinoma | Urothelial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Genetic analysis on isolated cells | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Urothelial neoplasia
- interventionNames
- Genetic: Genetic analysis on isolated cells
- label
- 2
- description
- Age-matched individuals free of neoplasia
- interventionNames
- Genetic: Genetic analysis on isolated cells
Primary outcomes (1)
- measure
- Prognostic role of the liquid biopsy
- timeFrame
- 2020-2023
- description
- Gene signature in CTC and UTC predicting tumor relapse
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosis of urothelial neoplasia, naive for therapy Exclusion Criteria: Absence of previous neolpastic disease or genetic diseases
References
Publications (0)
Data not yet available
No reference posted for this study.